[go: up one dir, main page]

DE60319240D1 - Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen - Google Patents

Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Info

Publication number
DE60319240D1
DE60319240D1 DE60319240T DE60319240T DE60319240D1 DE 60319240 D1 DE60319240 D1 DE 60319240D1 DE 60319240 T DE60319240 T DE 60319240T DE 60319240 T DE60319240 T DE 60319240T DE 60319240 D1 DE60319240 D1 DE 60319240D1
Authority
DE
Germany
Prior art keywords
treatment
ligands
antigen
solid tumors
bone cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319240T
Other languages
English (en)
Inventor
Veit Prof Dr Krenn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin filed Critical Charite Universitaetsmedizin Berlin
Application granted granted Critical
Publication of DE60319240D1 publication Critical patent/DE60319240D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60319240T 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen Expired - Lifetime DE60319240D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03029464A EP1544213B1 (de) 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Publications (1)

Publication Number Publication Date
DE60319240D1 true DE60319240D1 (de) 2008-04-03

Family

ID=34486276

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319240T Expired - Lifetime DE60319240D1 (de) 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Country Status (5)

Country Link
US (1) US20070148191A1 (de)
EP (1) EP1544213B1 (de)
AT (1) ATE386748T1 (de)
DE (1) DE60319240D1 (de)
WO (1) WO2005058966A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133822A1 (en) * 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
EP2313435A4 (de) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc An den fibroblastenwachstumsfaktorrezeptor 3 (fgfr3) bindende proteine
WO2010027370A1 (en) * 2008-09-08 2010-03-11 The Regents Of The University Of Michigan Compositions and methods for the treatment of solid tumor cancers
RU2539099C2 (ru) * 2009-04-13 2015-01-10 Апцет Гмбх Унд Ко.Кг Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
KR20230052963A (ko) 2020-08-21 2023-04-20 젠자임 코포레이션 Fgfr3 항체 및 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030124127A1 (en) * 2001-12-06 2003-07-03 Lijun Yang Targeting leukemia cells
AU2003210054A1 (en) * 2002-03-21 2003-10-08 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
JP2005535676A (ja) * 2002-07-19 2005-11-24 ラドウィッグ・インスティテュート・フォー・キャンサー・リサーチ 腫瘍の処置における放射免疫療法の効果の増強
WO2004060317A2 (en) * 2002-12-31 2004-07-22 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia

Also Published As

Publication number Publication date
EP1544213A1 (de) 2005-06-22
EP1544213B1 (de) 2008-02-20
WO2005058966A3 (en) 2005-09-01
ATE386748T1 (de) 2008-03-15
US20070148191A1 (en) 2007-06-28
WO2005058966A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE516818T1 (de) Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
ATE466885T1 (de) Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
ATE516042T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE60136099D1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
EP1257287A4 (de) Verbindungen und methoden zur frühdiagnose von eierstockkrebs
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1416960A4 (de) Vegfr-1-antikörper zur behandlung von brustkrebs
HK1056692A1 (en) Proteins
DE60319240D1 (de) Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen
ATE421324T1 (de) Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs
DE60224429D1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE602004003829D1 (de) 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
EP1663318A4 (de) Radioisotop-chitosan-komplex zur behandlung von prostatakrebs
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
EP1646385A4 (de) Verwendung von benzothiopenen zur behandlung und prävention von prostatakrebs

Legal Events

Date Code Title Description
8332 No legal effect for de